Procrit epoetin alfa: Phase III data

In a Phase III trial in 110 patients conducted by the Eastern Cooperative Oncology Group, 150 U/kg subcutaneous Procrit (EPO) plus SOC significantly improved erythroid response rate vs. SOC alone at 4 months (36% vs. 9.6%, p=0.002). After 4 months, non-responders crossed over, and those who continued to not respond received Neupogen filgrastim granulocyte colony-stimulating factor (G-CSF) from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Overall erythroid response rate to EPO with or without G-CSF was 46.6%. ...